The advantage of this approach is that it allows calculation of individualised risk prediction using available results and demographics such that a tailored approach could be considered that is, we could determine at a given level of risk of CRC what f‐Hb result (incorporating age, sex and FBC) should trigger referral for further investigation. The gene discussed is GSTM1; the disease is colorectal carcinoma.